Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hyperkalemia
Biotech
Toxicity knocks Ardelyx's hyperkalemia hopes back to preclinic
Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.
Phil Taylor
Nov 21, 2017 9:15am
Struggling Ardelyx cuts staff, places bets on its late-stage pipeline
Aug 9, 2017 9:26am
EuroBiotech Report: AstraZeneca, Novartis, $30M round and more
Mar 23, 2017 9:49am
AstraZeneca’s $2.7B ZS-9 rejected again by FDA
Mar 17, 2017 7:06am
AstraZeneca’s FDA delayed ZS-9 gains European thumbs-up
Feb 24, 2017 7:31am
Relypsa finally finds a buyer as Galenica coughs up $1.5B
Jul 21, 2016 7:51am